FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e Responses	s)														
Name and Address of Reporting Person * Norry Elliot				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK				3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021						X Officer (give title below) Other (specify below) Chief Medical Officer					
ON, X0 C	(Street) 0X14 4RX		4. If	Amendmen	t, Date	e Origi	nal F	iled(Mont	h/Day/Year	r)	_X_ Form fil	ed by One Repo	orting Person	•	ble Line)
	(State)	(Zip)		1	able	I - No	n-De	rivative	Securiti	es Acqui	ired, Disp	osed of, or I	Beneficially	Owned	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		Exect any	any		Code		(A) or Disposed of (Instr. 3, 4 and 5)		of (D)	D) Beneficially (Reported Train		y Owned Following Transaction(s) d 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					C	Code	V	Amoun	or	Price				(I) (Instr. 4)	
	•	01/19/2021				S		2,111	D	5.6695	3,539	3)		D	
eport on a s	separate line fo		· Deriva	ative Secur	ties A	cquir	Person the	sons whatained if form dis	no resp n this fo splays	orm are a curre eneficial	not requesting ntly valid	uired to res	spond unle	ss	1474 (9-02)
2. Conversion or Exercise Price of Derivative Security	Date	n 3A. Deemed Execution Da any	ate, if	4. te, if Transaction Code Year) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)		and Expiration Date (Month/Day/Year)		7. Ta	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct (or Indirect)	Beneficia Ownershi (Instr. 4)
											Amount				
F III	PTIMMUUBILEE ON, X0 Courity Deposita ag Ordina conversion or Exercise rice of Derivative	Address of Reporting Per Details of Conversion of Conversion of Exercise rice of Derivative (First) (First) (First) (First) (First) (Street) (Street)	Address of Reporting Person* Ot (First) (Middle) PTIMMUNE THERAPEUTICS UBILEE AVENUE, MILTON (Street) ON, X0 OX14 4RX (State) (Zip) 2. Transaction Date (Month/Day/Year) Proof of Perivative 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	Address of Reporting Person* Ot	Address of Reporting Person* 2. Issuer Name Adaptimmune Adaptimmune Adaptimmune Adaptimmune (First) (Middle) PTIMMUNE THERAPEUTICS UBILEE AVENUE, MILTON (Street) 4. If Amendment Adaptimmune (Month/Day/Year) Purity 2. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) Proport on a separate line for each class of securities beneficially of the conversion of the conversion Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Transaction Code (Instr. 8)	Address of Reporting Person* ot	Address of Reporting Person* Other Control (First) (Middle) PTIMMUNE THERAPEUTICS UBILEE AVENUE, MILTON (Street) 4. If Amendment, Date Original Properties (Month/Day/Year) ON, X0 OX14 4RX (State) (Zip) Table I - Note Execution Date, if (Month/Day/Year) Output (Month/Day/Year) 2. Transaction Date (Instr. 8) Code (Instr. 8) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, openivative Securities Acquired (A) or Disposed of (D) (Instr. 3) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3)	Address of Reporting Person* Oth	Address of Reporting Person* of the control of the	Address of Reporting Person by the control of the c	Address of Reporting Person* Ott Ott Ott Ott Ott Ott Ott O	Address of Reporting Person* Adaptimmune Therapeutics PLC [ADAP] (First) (Middle) PTIMMUNE THERAPEUTICS UBILEE AVENUE, MILTON (Street) A. If Amendment, Date Original Filed(Month/Day/Year) (Street) A. If Amendment, Date Original Filed(Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3) Amount (ID) Price Deport on a separate line for each class of securities beneficially owned directly or indirectly. Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) A. Transaction (Instr. 3) A. Deemed (Instr. 8) Code V Amount (ID) Price Persons who respond to the collect contained in this form are not required for many (Instr. 3) A. Transaction (Instr. 3) A. Deemed (Instr. 8) Persons who respond to the collect contained in this form are not required for many (Instr. 3) A. Deemed (Instr. 8) A. Transaction (Instr. 3) A. Deemed (Instr. 8) A. Securities Acquired (A) or Disposed of, or Beneficially Owned directly or indirectly. Persons who respond to the collect contained in this form are not required the form displays a currently valid and Expiration Date (Instr. 8) A. Transaction (Month/Day/Year) A. Transaction (Instr. 8) Deport on a separate line for each class of securities Acquired (A) or Disposed of (Instr. 8) Deport on a separate line for each class of securities beneficially owned directly or indirectly. A. Code (Instr. 8) A. Deemed (Instr. 8) A. Securities Acquired (A) or instruction (Instr. 8) A. Securities Acquired (A) or instruction (Instr. 8) A. Securities Acquired (A) or instruction (Instr. 8) A. Deemed (In	Address of Reporting Person* to	Address of Reporting Person Adaptimmune Therapeuties PLC [ADAP] (First) (Middle) PTIMMUNE THERAPEUTICS UBILEE AVENUE, MILTON 4. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Street) (Street) (Street) (A. If Amendment, Date Original Filed(Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Address of Reporting Persons* Adaptimmune Therapeutics PLC [ADAP] Adaptimmune Therapeutics PLC [ADAP] S. Relationship of Reporting Person(s) to Issue (Check all applicable) 10% owner (

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Norry Elliot C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK ABINGDON, X0 OX14 4RX			Chief Medical Officer			

Signatures

/s/ Elliot Norry	01/19/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which vested on January 16, 2021. Once
- (1) vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from \$5.64 to \$5.72, inclusive. Upon request, (2) the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
- (3) The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 6,793 ADSs and RSU-style options and other options covering an aggregate of 2,395,766 ordinary shares of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.